Medicine and Dentistry
Patient
82%
Corticosteroid
39%
Salazosulfapyridine
39%
Mesalazine
39%
Adverse Event
35%
Spontaneous Remission
35%
Crohn's Disease
21%
Therapeutic Procedure
17%
Drug Megadose
14%
Low Drug Dose
14%
Analysis
14%
Budesonide
10%
Crohn's Disease Activity Index
7%
Dimemorfan Phosphate
7%
Olsalazine
7%
Treatment Duration
3%
Combination Therapy
3%
Nausea
3%
Headache
3%
Abdominal Pain
3%
Diarrhea
3%
Granulomatous Colitis
3%
Clinical Endpoint
3%
Assessment
3%
Association
3%
Consensus
3%
Amaurosis
3%
Language
3%
Systematic Review
3%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Sulfasalazine
39%
Aminosalicylic Acid
39%
Corticosteroid
39%
Adverse Event
35%
Remission
35%
Crohn Disease
21%
Random Effects Model
14%
Randomized Controlled Trial
14%
Budesonide
10%
Olsalazine
7%
Dimemorfan Phosphate
7%
Clinical Trial
7%
Controlled Release
7%
Nausea
3%
Combination Therapy
3%
Abdominal Pain
3%
Diarrhea
3%
Headache
3%
Delayed Release
3%
Blindness
3%
INIS
patients
82%
risks
67%
corticosteroids
39%
data
32%
diseases
28%
doses
28%
comparative evaluations
25%
induction
14%
therapy
7%
reviews
7%
randomness
7%
data analysis
3%
tools
3%
clinical trials
3%
assessments
3%
reduction
3%
colleges
3%
proceedings
3%
pain
3%
extraction
3%
libraries
3%
sensitivity analysis
3%
nausea
3%
diarrhea
3%
vomiting
3%
Neuroscience
Placebo
50%
Mesalazine
39%
Sulfasalazine
39%
Budesonide
10%
Randomized Controlled Trial
7%
Olsalazine
7%